Evogene Ltd.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -98.4% over 5Y.
today you would have $15.75▼ -98.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.10 | $1.87 | $8.40 | $7.00 | |
| P/S | 8.4x | 2.5x | 2.2x | 14.2x | 17.2x |
| P/B | — | — | — | 3.5x | 1.0x |
| EPS | -$1.08 | -$2.89 | -$5.20 | -$6.50 | |
| Profit margin | -548.18% | -220.22% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| XWELXWELL, Inc. | $1.01 | — | 20.6x | — | -361.36% | $8.68M |
| MGRXMangoceuticals Inc | $0.40 | — | 0.6x | — | -95.10% | $8.67M |
| NDRAENDRA Life Sciences Inc. | $5.80 | — | 1.4x | — | -152.04% | $8.7M |
| CODXCo-Diagnostics, Inc. | $1.21 |
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Company description provided by Yahoo Finance.
| -295.59% |
| -800.77% |
| -1590.33% |
| ROE | — | — | — | -198.12% | -95.37% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.5x |
| — |
| -174.77% |
| $8.45M |
| XCURExicure Inc | $1.29 | — | 3.9x | — | -168.37% | $8.44M |
| IMNNImunon, Inc. | $1.60 | — | 3.9x | — | -429.72% | $8.98M |